ReviewJapanese guideline for the treatment of idiopathic pulmonary fibrosis
Introduction
In recent years, there has been a worldwide move toward measures to standardize clinical practice in the treatment of diseases. As idiopathic pulmonary fibrosis (IPF) is the form of idiopathic interstitial pneumonias (IIPs) with the poorest prognosis and an intractable condition, recent years have seen many drugs put forward as candidates in clinical trials for assessment of their efficacy and safety. Back in 2000, a consensus statement on IPF treatment was formulated by bodies chiefly in Europe and North America [1]. Subsequently a number of scientifically based randomized controlled trials (RCT) were planned and carried out, which resulted in the accumulation of evidence-based medicine (EBM) in literatures. It was on the basis of these results that the first EBM guideline was created in 2011 [2].
In Japan, the Manual for the Diagnosis and Treatment of Idiopathic Interstitial Pneumonias was issued in 2004 [3] with the aim of establishing consistency with the European and North American consensus statement. The end of 2008 brought a world-first development with the marketing of the antifibrotic agent pirfenidone. To coincide with the 2011 issue of the EBM guideline, its content was incorporated in the Manual for the Diagnosis and Treatment of Idiopathic Interstitial Pneumonias (revised 2nd edition) published in the same year. Between 2012 and the end of 2014 the results of further international clinical trials have been reported, leading to the revision of the European and North American EBM guideline on IPF treatment in 2015 [4].
Building on this background situation toward the issue of a scientifically based guideline for Japan, the present guideline was formulated on the basis of clinical trial results from Japan and overseas and Japanese post-marketing surveillance data. The main aim of the present guideline is to outline practically effective therapies and measures for patients based on appropriate diagnosis of IPF. However, the present guideline is designed strictly to give recommendations of various strengths in accordance with the GRADE system and does not limit the discretion of the treating physician based on assessment of patient benefit. We also wish to make clear that it is not intended as supporting material for decisions in medical disputes or medical-related litigation. When non-standard therapies or measures are introduced, the patient should be given an adequate explanation and a relevant entry should be made in the medical notes.
The use of the present guideline is not limited to physicians specializing in the diagnosis and treatment of respiratory diseases, but is also aimed at non-specialist doctors, medical treatment staff, patients, and their families.
A clinical practice guideline that can be used with confidence is defined as ‘a document including recommendations which is intended to optimize patient care and is based on systematic review of the evidence and an assessment of the benefits and harms of a number of treatment options.’ Meanwhile, the website of the Minds Guideline Center, which promotes evidence-based medical information as one of the functions of the Japan Council for Quality Health Care, states that ‘a clinical practice guideline is a document including scientifically based and systematically formulated recommendations which is created for the purpose of supporting patients and medical professionals and which can be used as one basis for judgment when making decisions in the clinical setting.’ It further states that ‘a clinical practice guideline does not negate the experience of medical professionals, and as the guideline content refers to clinical practice in general, it may not necessarily be applicable depending on the individual patient׳s condition.’ It thus remains of prime importance that the final judgment in the clinical setting is made by the treating physician in discussion with the patient.
Section snippets
Committee composition
The IPF treatment guideline is a guideline specifically addressing treatment and management which was created with the collaboration of the Japanese Respiratory Society (JRS) under the leadership of the Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases. Hitherto in Japan, the document used to support decision-making at the frontline of clinical practice for IPF and other idiopathic interstitial pneumonias
The GRADE system and self-assessment
Quality of evidence and terminology used for the recommendation show Table 1 and Table 2. In this clinical practice guideline formulated using the GRADE system, self-assessment shows in Table 3. Since its presentation in 2004, the GRADE system has benefited from the accumulation of experience and discussion by many relevant practitioners around the world, which has contributed to growing methodological refinement and the consolidation of its core elements. At present, the resulting insights can
Recommendations for specific treatment questions
Fig. 1 shows clinical questions for treatment of IPF.
Clinical Question 1: Should patients with IPF be treated with corticosteroid monotherapy?
We recommend strongly that patients with IPF in the chronic phase should not be treated with corticosteroid monotherapy.
Conclusions
Since its presentation in 2004, the GRADE system has benefited from the accumulation of experience and discussion by many relevant practitioners around the world, which has contributed to growing methodological refinement and the consolidation of its core elements. At present, the resulting insights can be expressed in the seven criteria outlined above. The GRADE working group regards these as essential requirements, but as stated in Criterion 4, the formulation of evidence profiles in a fixed
Future directions
The existing evidence on IPF is characterized by the very small number of RCTs available and by the resulting necessity to turn to observational study. In the systematic review for the formulation of the present guideline, difficulties were consequently encountered in both the integration of RCT findings and in the assessment of the quality of the observational study. In frequent instances, the specialists disagreed among themselves as to the interpretation and evaluation of the individual
Revision schedule
It is planned to revise the present guideline every 4–5 years in response to the results of new clinical trials, etc. However, in the case of important findings, consideration will be given as necessary to bringing forward the revision date or undertaking partial revision.
Funding
The formulation of the present guideline was funded exclusively with survey and research grants from the Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases.
Conflict of interest
In line with the Japanese Respiratory Society׳s conflict of interest policy, which is based on the Policy of Conflict of Interest in Clinical Research adopted jointly by the Japan Society of Internal Medicine and other scientific societies, all 34 committee members were requested to declare conflict of interest status with respect to economic relationships with enterprises involved in IPF or related diseases in accordance with the criteria listed below.
- (1)
Any service as officer, advisor, etc., to
Acknowledgments
The authors are grateful to external assessment committee members (Shoji Kudoh: The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association, Yukihiko Sugiyama: Japan Association for Development of Community Medicine, Nerima-Hikarigaoka Hospital, Toshihiro Nukiwa: Japan Anti-Tuberculosis Association, Research Institute of Tuberculosis), and collaborators (Takekazu Iwata: Chiba University, Graduate School of Medicine, Department of General Thoracic Surgery, Ryo Ko: Juntendo
References (94)
- et al.
Steroids in idiopathic pulmonary fibrosis; a prospective assessment of adverse reactions, response to therapy, and survival
Am J Med
(2001) - et al.
Autoimmune-featured interstitial lung disease: a distinct entity
Chest
(2011) - et al.
Cyclosporine A combined with low-dose corticosteroid treatment in patients with idiopathic pulmonary fibrosis
Respir Investig
(2015) - et al.
Autoimmune-featured interstitial lung disease: a distinct entity
Chest
(2011) - et al.
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY); two randomised trials
Lancet
(2011) - et al.
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis
Respir Investig
(2015) - et al.
Pulmonary rehabilitation in interstitial lung disease; benefits and predictors of response
Chest
(2009) - et al.
Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review
Eur J Intern Med
(2008) - et al.
Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis
Chest
(2015) - et al.
Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study
Pulm Pharmacol Ther
(2014)
Operation for lung cancer in patients with idiopathic pulmonary fibrosis; surgical contraindication?
Ann Thorac Surg
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias
Lung Cancer
The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias
J Thorac Oncol
Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer
Clin Lung Cancer
Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema
Lung Cancer
Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)
Am J Respir Crit Care Med
ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement; idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management
Am J Respir Crit Care Med
An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline
Am J Respir Crit Care Med
Idiopathic pulmonary fibrosis
N Engl J Med
Corticosteroids for idiopathic pulmonary fibrosis
Cochrane Database Syst Rev
Acute exacerbation in idiopathic interstitial pneumonia
Jpn J Thorac Dis
Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis; a prospective double-blind, randomized, placebo-controlled clinical trial
Am Rev Respir Dis
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis
N Engl J Med
A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis
Respirol
Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis
Respirology
An assessment of clinical efficacy of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis
Nihon Kyobu Rinsho [Jpn]
Effect of inhaled N-acetylcysteine monotherapy and redox balance in idiopathic pulmonary fibrosis
Clin Respir Physiol [Jpn]
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
Pirfenidone in idiopathic pulmonary fibrosis
Eur Respir J
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
N Engl J Med
Correction: pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis
PLoS One
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis
N Engl J Med
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
N Engl J Med
Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis
Intern Med
Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study
Respirology
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Eur Respir J
Long-term oxygen therapy in parenchymal lung diseases: an analysis of survival
Eur Respir J
Idiopathic pulmonary fibrosis; impact of oxygen and colchicine, prednisone, or no therapy on survival
Am J Respir Crit Care Med
A retrospective study of prognostic factors in patients with interstitial pneumonia receiving long-term oxygen therapy
Lung
Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
Respirology
Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease
Thorax
Effect of pulmonary rehabilitation in patients with idiopathic interstitial pneumonias—comparison of the completed group with the dropout group
J Jpn Soc Respir Care Rehabil
Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis
Respir Care
Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis
Lung
Prediction of outcome after acute exacerbation of idiopathic interstitial pneumonia
Jpn J Thorac Dis
Cited by (72)
Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition
2024, Respiratory InvestigationPulmonary fibrosis and type-17 immunity
2023, Respiratory InvestigationIdiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
2023, Disease-a-MonthCitation Excerpt :Hence, there is a need for further RCTs to elucidate the effects of staying put on the same antifibrotic, switching to another one, or using a combination of different agents in patients with deteriorating lung capacity. Corticosteroids, including the pulse therapy, has been recommended as the treatment for an acute exacerbation of IPF, according to the 2018 Japanese guidelines.310 The pulse treatment is usually dispensed for three days in a row; it may be dispensed again once or twice on a weekly basis.
Interstitial Lung Disease: A Focused Review for the Emergency Clinician
2023, Journal of Emergency Medicine